2017-07-30T06:46:36+03:00[Europe/Moscow] en true Ezetimibe, Niacin, Gemfibrozil, Lomitapide, Nafenopin, Benfluorex, SCH-48461, Niacin/lovastatin, Niacin/simvastatin, Evacetrapib, Mipomersen, Torcetrapib, Acipimox, Meglutol, Nicotinyl alcohol, SCH 900271, Ezetimibe/atorvastatin, Dextrothyroxine, Ezetimibe/simvastatin, Magnesium pyridoxal 5-phosphate glutamate, Tiadenol, Bococizumab, Lapaquistat, Roxibolone, Clomestrone, Mytatrienediol, Acetiromate flashcards
Hypolipidemic agents

Hypolipidemic agents

  • Ezetimibe
    Ezetimibe is a drug that lowers plasma cholesterol levels.
  • Niacin
    Niacin, also known as vitamin B3 and nicotinic acid, is an organic compound with the formula C6H5NO2 and, depending on the definition used, one of the 20 to 80 essential human nutrients.
  • Gemfibrozil
    Gemfibrozil is the generic name for an oral drug used to lower lipid levels.
  • Lomitapide
    Lomitapide (INN, marketed as Juxtapid in the US and as Lojuxta in the EU) is a drug used as a lipid-lowering agent for the treatment of familial hypercholesterolemia, developed by Aegerion Pharmaceuticals.
  • Nafenopin
    Nafenopin is a hypolipidemic agent.
  • Benfluorex
    Benfluorex is an anorectic and hypolipidemic agent that is structurally related to fenfluramine patented and manufactured by a French pharmaceutical company Servier.
  • SCH-48461
    SCH-48461 is a cholesterol absorption inhibitor.
  • Niacin/lovastatin
    Niacin/lovastatin (trade names Advicor, Mevacor) is a drug combination used for the treatment of dyslipidemia.
  • Niacin/simvastatin
    Niacin/simvastatin (trade name Simcor, by Abbott) is a combination drug consisting of an extended release form of the vitamin niacin and the statin drug simvastatin.
  • Evacetrapib
    Evacetrapib was a drug under development by Eli Lilly & Company (investigational name LY2484595) that inhibits cholesterylester transfer protein (CETP), which transfers and thereby increases high-density lipoprotein and lowers low-density lipoprotein (CETP inhibitor]. It is thought that modifying lipoprotein levels modifies the risk of cardiovascular disease. The first CETP inhibitor, torcetrapib, was unsuccessful because it increased levels of the hormone aldosterone and increased blood pressure, which led to excess cardiac events when it was studied. Evacetrapib does not have the same effect. When studied in a small clinical trial in people with elevated LDL and low HDL, significant improvements were noted in their lipid profile.
  • Mipomersen
    Mipomersen (previously ISIS 301012, trade name Kynamro) is a cholesterol-reducing drug.
  • Torcetrapib
    Torcetrapib (CP-529,414, Pfizer) was a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.
  • Acipimox
    Acipimox (trade name Olbetam in Europe) is a niacin derivative used as a lipid-lowering agent.
  • Meglutol
    Meglutol (INN, also known as 3-hydroxy-3-methylglutaric acid, β-hydroxy-β-methylglutaric acid, and dicrotalic acid) is a hypolipidemic agent.
  • Nicotinyl alcohol
    Nicotinyl alcohol (pyridylcarbinol) is a niacin derivative used as a hypolipidemic agent and as a vasodilator.
  • SCH 900271
    SCH 900271 is a nicotinic acid derivative designed to treat dyslipidemia.
  • Ezetimibe/atorvastatin
    Ezetimibe/atorvastatin (brand name Liptruzet) is a cholesterol lowering combination drug.
  • Dextrothyroxine
    Dextrothyroxine (trade name Choloxin) saw research as a cholesterol-lowering drug but was pulled due to cardiac side-effects.
  • Ezetimibe/simvastatin
    Ezetimibe/simvastatin /ɛˈzɛtᵻmɪb ˌsɪmvəˈstætᵻn/ is a drug combination used for the treatment of dyslipidemia.
  • Magnesium pyridoxal 5-phosphate glutamate
    Magnesium pyridoxal 5-phosphate glutamate (trade name Sedalipid) is a hypolipidemic agent.
  • Tiadenol
    Tiadenol is a hypolipidemic agent.
  • Bococizumab
    Bococizumab (RN316) is a drug in development by Pfizer targeting PCSK9 to reduce LDL cholesterol.
  • Lapaquistat
    Lapaquistat (TAK-475) is a cholesterol-lowering drug.
  • Roxibolone
    Roxibolone (INN) (developmental code name BR-906), also known as 11β,17β-dihydroxy-17α-methyl-3-oxoandrosta-1,4-diene-2-carboxylic acid, is a steroidal antiglucocorticoid described as an anticholesterolemic (cholesterol-lowering) and anabolic drug which was never marketed.
  • Clomestrone
    Clomestrone (brand names Arterolo, Atheran, Colesterel, Iposclerone, Liprotene, Persclerol, others; former developmental code name SC-8246), also known as 16α-chloroestrone 3-methyl ether, is a semisynthetic, steroidal, weak estrogen derived from estrone and used as an anticholesterolemic agent in the treatment of atherosclerosis.
  • Mytatrienediol
    Mytatrienediol (developmental code name SC-6924; former tentative trade names Manvene, Anvene), also known as 16α-methyl-16β-epiestriol 3-methyl ether or 16β-hydroxy-16α-methylestradiol 3-methyl ether, is a semisynthetic, steroidal, weak estrogen and estrogen ether derived from estriol that was developed in the late 1950s but was never marketed.
  • Acetiromate
    Acetiromate is an antilipidemic drug which is used to treat hyperlipidemia.